19 patents currently held
11 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2028. from the record
Of the 11 now held by other companies, 11 name Seagen Inc. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
Jan 2028
Next term end
3
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2028 · High confidence
Also notable
Ends Oct 2031 · High confidence
Also notable
Ends Aug 2029 · High confidence
Prostate Stem Cell Antigen (PSCA) Variants and Subsequences Thereof
US 7,622,564
The most cited patent in this portfolio, cited by 28 later US patents, top 25% of utility patents granted in 2009 in our data. Protection runs to 2028.
Antibody Drug Conjugates (ADC) That Bind to 161P2F10B Proteins
US 8,609,092
The largest patent family in this portfolio, 94 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Antibodies and Related Molecules That Bind to 24P4C12 Proteins
US 8,039,597
Renewed at every maintenance window since the 2011 grant; no more fees are due before its term ends in 2029.
Formerly held, still cited
Notable
Ends Sep 2031 · Medium confidence
A family of 94 related applications built on the 2021 grant. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
now held by Seagen Inc.
Also notable
Ends Aug 2030 · High confidence
Renewed at every maintenance window since the 2012 grant; no more fees are due before its term ends in 2030.
now held by Seagen Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Feb 8 to 28, 2027 · next Feb 8
- 1 fee due Oct 12, 2027The maintenance fee for Antibody Drug Conjugates (ADC) That Bind to 161P2F10B Proteins (US 9,308,278) comes due Oct 12, 2027. Unpaid by Apr 12, 2028, it lapses early.
- 1 fee due Nov 12, 2027The maintenance fee for Antibody Drug Conjugates (ADC) That Bind to CD37 Proteins (US 10,646,583) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 2 largest of its 3 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Antibody Drug Conjugates (ADC) That Bind to 161P2F10B Proteins | 17 in force | to Jun 2042 |
| Prostate Stem Cell Antigen (PSCA) Variants and Subsequences Thereof | 1 in force | to Jan 2028 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,622,564 | Prostate Stem Cell Antigen (PSCA) Variants and Subsequences Thereof In force · High confidence | In force | High confidence | |
| US 8,039,597 | Antibodies and Related Molecules That Bind to 24P4C12 Proteins In force · High confidence | In force | High confidence | |
| US 9,308,278 | Antibody Drug Conjugates (ADC) That Bind to 161P2F10B Proteins In force · High confidence | In force | High confidence | |
| US 8,609,092 | Antibody Drug Conjugates (ADC) That Bind to 161P2F10B Proteins In force · High confidence | In force | High confidence | |
| US 9,925,273 | Antibody Drug Conjugates (ADC) That Bind to CD37 Proteins In force · High confidence | In force | High confidence | |
| US 10,646,583 | Antibody Drug Conjugates (ADC) That Bind to CD37 Proteins In force · High confidence | In force | High confidence | |
| US 11,633,500 | Antibody Drug Conjugates (ADC) That Bind to CD37 Proteins In force · High confidence | In force | High confidence | |
| US 11,312,748 | Derivatives of Dolaproine-Dolaisoleucine Peptides In force · High confidence | In force | High confidence | |
| US 12,612,429 | Derivatives of Dolaproine-Dolaisoleuine Peptides In force · High confidence | In force | High confidence | |
| US 9,974,865 | Antibody Drug Conjugates (ADC) That Bind to FLT3 Proteins In force · High confidence | In force | High confidence |
Also on record, not counted in the 19: 11 patents in force now held by others · 131 patents ended · 12 applications pending · 62 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.